Groundbreaking Treatment for Early-Stage Breast Cancer Now Offered at Bon Secours Cancer Institute at DePaul

Monday, September 18, 2017

Breast Microseed Treatment® offers women one-time, one-hour outpatient cancer treatment

Bon Secours Cancer Institute at DePaul announced today that the Radiation Oncology department is now one of only three sites in the U.S., and the only in the southeast, to offer the latest in radiation therapy for early stage breast cancer: Breast Microseed Treatment®.    

Breast Microseed Treatment® is a new radiation therapy option that helps prevent the recurrence of cancer by treating the surgical site and surrounding tissue after the cancerous tumor is removed. The new treatment is similar to seed radiation therapy that’s been successful in treating prostate cancer for over 30 years. For this treatment, radiation oncologists place tiny titanium seeds filled with radioactive palladium (Pd-103) in the breast around the “at-risk” area. The seeds deliver a low dose of radiation over 60 – 90 days. After treatment, the seed casings are harmless and can remain in the breast.  

“The breast seeds offer similar treatment results to traditional external beam radiation therapy, but treatment is completed in a one-time, one-appointment procedure instead of sometimes more than 30 treatment sessions,” said Bradley Prestidge, MD, MS, FABS, Regional Medical Director for Radiation Oncology and world-renowned radiation oncologist with Bon Secours Oncology Specialists.

“Because the treatment is delivered within the breast tissue, we use less radiation. As a result, patients experience significantly reduced side effects. This one-time treatment option also helps patients receive more convenient cancer care so they can move along with their life.”    

While Bon Secours is the third site in the U.S. to offer the treatment option, it's been used in Canada and Europe since 2004. Breast Microseed Treatment® uses an FDA-listed device proven safe and effective over 13 years of academic rigor and clinical testing. Through independent, peer-reviewed evaluation, the clinical outcomes from Breast Microseed Treatment® have proven to be equivalent to other forms of radiation therapy.  

“This is an exciting breakthrough in treatment much like the introduction of prostate seed implantation was over 30 years ago. I’m very pleased we can offer women this new option for breast cancer treatment,” said Michele Nedelka, MD, radiation oncologist with Bon Secours Oncology Specialists. “However, it’s important to note that Breast Microseed Treatment® isn’t for everyone. Patients must be over 50 years old and have an early-stage cancer to be an appropriate candidate.”  

For more information or to schedule an appointment, call 757-278-2200.